Market research
EVFM Evofem Biosciences Inc
PINK USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 795K
- P/E ratio
- Not available
- Analyst target
- 225
- Dividend yield
- Not available
- Beta
- -1.36
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 795K
- P/E ratio
- Not available
- Analyst target
- 225
- Dividend yield
- Not available
- Beta
- -1.36
About
About Evofem Biosciences Inc
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Research context
Evofem Biosciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EVFM discussion.
5 years, 6 months ago
Evofem Biosciences, Inc is currently in a long term downtrend where the price is trading 55.6% below its 200 day moving average.
From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 281.6.
Evofem Biosciences, Inc's total revenue rose by inf% to $168K since the same quarter in the previous year.
Its net income has dropped by 219.2% to $-41M since the same quarter in the previous year.
Finally, its free cash flow fell by 198.1% to $-40M since the same quarter in the previous year.
Based on the above factors, Evofem Biosciences, Inc gets an overall score of 2/5.